Christine Günther


Dr. Christine Günther has been Chief Executive Officer, Chief Medical Officer and Qualified Person at apceth Biopharma since 2008 (then apceth). She is a specialist in clinical hematology and oncology with extensive experience in clinical stem cell transplantation, transplantation immunology and cell therapies. Her particular area of expertise is pharmaceutical development of complex cell-based and gene therapy products.
Before joining apceth, Christine Günther worked as qualified person, head of quality control and medical director at the German public stem cell and cord blood bank. Her work there focused on stem cell and tissue procurement, donor testing and characterization of cell products – including cord blood products – and their application to the patient in the treatment of malignant diseases. Before that she gained extensive experience as a hematologist/oncologist at the University Hospital in Munich, Germany.

Dusan Kosijer


Dusan Kosijer has served as Chief Financial Officer of apceth since October 2016. Prior to joining apceth, Mr. Kosijer served as CFO for Accovion GmbH, a Contract Research Organization (CRO) headquartered close to Frankfurt. Throughout his career, he has gained more than 14 years’ experience in the healthcare sector. Mr. Kosijer is Certified Management Accountant by training.

Ulrike Verzetnitsch


Ulrike Verzetnitsch joined apceth Biopharma in 2015 as Chief Technical Officer. In this role, she is responsible for all GMP operation activities, including the manufacturing and quality control of apceth Biopharma’s own products and the CMO-business.

Ulrike Verzetnitsch began her career at Baxter in Vienna in 2000. Within Baxter, she was responsible for final container production of aseptic blood plasma products, vaccines and recombinants of commercial and clinical products. In 2010 she joined Takeda, where she was responsible for manufacturing of aseptic/sterile liquid and lyophilized as well as non-sterile liquid and semi-solid commercial products.